TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note released on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

NASDAQ TCON opened at $0.03 on Tuesday. The business’s fifty day moving average is $0.04 and its 200 day moving average is $0.26. The company has a market capitalization of $109,802.00, a PE ratio of 0.01 and a beta of 1.37. TRACON Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.75.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.